Advances in bioinformatics and genomic dataanalysis have enabled the identification of cancer antigens that are generallyoverlooked during immune surveillance; these neoantigens have been shown topossess substantial therapeutic potential
Theuse of neoantigens in therapy has demonstrated the ability to elicit a strong Tcell mediated immune response. Several therapy candidates are beinginvestigated both as monotherapies and in combination with various immunecheckpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, andnivolumab. Of these, certain pipeline candidates have already entered mid tolate-stage (phase II and above) trials and are anticipated to enter the market overthe next 5-10 years.
To order this 320+ page report,which features 110+ figures and 140+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Key Market Insights
Over 150+ candidate therapies in the development pipeline
Nearly13% of the pipeline therapies are being developed for the treatment of GIcancers, followed by lung cancer (11%). Examples of molecules being developedfor the aforementioned indications include (in alphabetical order, nospecific selection criteria) MicOryx, NCI-4650, and Tedopi®.
1,100+ patents filed / granted in 2018
In fact, more than 6,000 patents were filed / granted relatedto neoantigen targeted therapies, since 1978. Based on existing intellectualproperty, the R&D activity was observed to be concentrated in the US. Otherkey regions with significant intellectual capital include (in decreasingorder of number of patents filed / granted) Australia, Europe, China, and Canada.
Close to USD 7.5 billion invested by both private andpublic investors, since 2014
Around USD 3,200 million was raised through venture capitalfinancing, representing around 43% of the total capital raised by industryplayers in the given time period (till April 2019). Further, in the last fiveyears, there have been 10 IPOs accounting for more than 800 million infinancing of neoantigen related initiatives.
Companies are collaborating actively for the advancement ofclinical trials
Majority of the abovementioned agreements were observed tobe focused on conducting Phase I / Phase II clinical studies of neoantigentargeted therapies for the treatment of different cancer indications. Agreementssigned for research purposes (19%) were also observed to be popular amongindustry stakeholders, during 2014-2019 (till April).
More than 350 publications havebeen published since 2014
It is worth noting that between the period 2014-2019, over150 research articles were published related to neoantigen targeted therapies.Further, more than 190 review articles have been published related to thisupcoming field.
Therapies using personalized neoantigens are anticipated toincrease at a CAGR of over 60% between 2024 and 2030
This growth is anticipated to be primarily driven by the reducedrisk of adverse effects and improved efficacy of personalized therapies.North America (primarily the US) and Europe are expected to capture themajority share by 2030, in terms of the sales-based revenues.
PressRelease: Current Format
Torequest a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/257/request-sample.html
Key Questions Answered
§ What are the prevalent trends related to R&D activityfocused on neoantigen based therapies?
§ What are the clinical conditions for which neoantigentargeted therapies are being developed?
§ What are the key challenges faced by neoantigen-basedtherapy developed?
§ Who are the leadingindustry and non-industry players?
§ What are the key factorsthat are likely to influence the evolution of the neoantigen targeted therapiesmarket?
§ What are the reasonsfor partnership activity among stakeholders in this industry?
§ Who are the keyinvestors in neoantigen targeted therapies?
§ What is share of neoantigentargeted therapies in the immunotherapy market?
§ How is the current and future market opportunity likely tobe distributed across key market segments and geographies?
The USD 3 billion (by 2030)financial opportunity within the neoantigens market has been analyzed acrossthe following segments:
§ Type of targetdisease indication
§ Bone cancer
§ Colorectal cancer
§ Gynecological cancer
§ Non-small cell lungcancer
§ Renal cell carcinoma
§ Other cancers
§ Type of neoantigens
§ Personalized neoantigens
§ Type of immunotherapy
§ Dendritic cellvaccines
§ DNA / RNA-basedvaccines
§ Protein /peptide-based vaccines
§ TIL-based therapies
§ Route ofadministration
§ Other routes
§ Key geographicalregions
§ North America
§ Rest of the World
Thereport features inputs from eminent industry stakeholders, according to whom neoantigentargeted therapies are expected to be the next big step in cancerimmunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstratedsignificant therapeutic potential and promising clinical outcomes. Thereport includes detailed transcripts of discussions held with the followingexperts:
§ GabrielNistor (Chief Science Officer, AIVITA Biomedical)
§ EllaSorani (Vice President Research and Development, BioLineRx)
§ Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)
PressRelease: Current Format
Theresearch covers detailed profiles, featuring an overview of the company, itsfinancial information (if available),and a description of its product(s), highlighting type of therapy, currentdevelopment status, and key preclinical / clinical trial results. Each profilealso includes a list of recent developments, and an informed opinion on thelikely strategies that may be adopted by these players to fuel growth in theforeseen future.
§ Bavarian Nordic
§ Genocea Biosciences
§ Neon Therapeutics
§ Precision Biologics
§ Vaxon Biotech
Foradditional details, please visit
Youmay also be interested in the following titles:
1. T-Cell Immunotherapies Market (4th Edition), 2019-2030
2. Novel Immuno-Oncology BiomarkerTesting Market,2019-2030
3. Companion Diagnostics Market (2nd Edition), 2019-2030
+1 (415) 800 3415